There continues to be debate about optimal eating times and patterns for weight management and glycemic control in people with T2D. Intermittent fasting or early time-restricted eating (eTRE) has succeeded in clinical trials and gained popularity. The impact of a 72 - hour induction fast is a novel approach to amplify the benefits of eTRE in type 2 diabetes.The aim of this study is to determine the effects of 72 - hour induction fast on T2D patients undergoing 3 months of eTRE.In this single cohort experimental study, participants were randomized into either an initial 72 - hour induction fast group or a non-induction fast group. Both groups underwent an 8 - hour feeding window (8 AM to 4 PM) and a 16 - hour fasting window daily for 3 months.Participants were recruited from a network of healthcare centers of FQHC and were required to have a T2D diagnosis and diabetes medication therapy. A total of 17 participants enrolled with 11 completing the study. Key exclusion criteria included recent AKI or DKA. At baseline and 12 - weeks blood draws were performed to analyze glycemic and lipid profiles, and anthropometrics, number of medications, and blood pressure were measured.Paired t-tests showed there were no significant differences in results between the two groups. Induction Fast + eTRE group (n = 4), the pre - and post - data mean, respectively were A1c (7.9% vs 7.7%, p = 0.7), weight (265 vs 259 lbs., p = 0.09), BMI (37.8 vs 37.1, p = 0.12), & systolic bp (123 vs 112 mmHg, p = 0.05). For the non-Induction Fast + eTRE group (n = 7), the pre- and post-data mean, respectively were A1c (7.6% vs 7.7%, p = 0.69), weight (231 vs 227 lbs., p = 0.01), BMI (36 vs 33, p = 0.03), & systolic bp (122 vs 118, p = 0.46).This pilot study demonstrates that a 72 - hour Induction Fast resulted in a significant reduction in blood pressure whereas eTRE alone showed significant reductions in weight and BMI. Further planned analysis of blood chemistries may illustrate the additional benefits of a 72 - hour Induction Fast on eTRE.

Disclosure

A. Nijjar: None. K. Shaikh: None. T.L. Calinawan: None. I. Maldonado: None. G. Jones: None. J.H. Shubrook: Consultant; Abbott Diagnostics. Advisory Panel; Bayer Inc., Eli Lilly and Company, Madrigal Pharmaceuticals, Inc., Nevro Corp. Consultant; Novo Nordisk, Sanofi.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.